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Abstract
Whether inflammation mediates how reproductive events affect chronic-disease risk is
unclear. We studied inflammatory biomarkers in the context of reproductive events using
National Health and Nutrition Examination Survey (NHANES) data. From 15,986 eligible
women from the 1999–2011 data cycles, we accessed information on reproductive events,
blood counts, C-reactive protein (CRP), and total homocysteine (tHCY). We calculated
blood-count ratios including: platelet-lymphocyte (PLR), lymphocyte-monocyte (LMR),
platelet-monocyte (PMR), and neutrophil-monocyte (NMR). Using sampling weights per
NHANES guidelines, means for counts, ratios, or biomarkers by reproductive events were
compared using linear regression. We performed trend tests and calculated p-values with
partial sum of squares F-tests. Higher PLR and lower LMR were associated with nulliparity.
In postmenopausal women, lower PMR was associated with early age at first birth and
higher NMR with later age at and shorter interval since last birth. Lower PNR and higher
neutrophils and tHCY were associated with early natural menopause. In all women, the neu-
trophil count correlated positively with CRP; but, in premenopausal women, correlated
inversely with tHCY. Reproductive events leave residual signatures on blood counts and
inflammatory biomarkers that could underlie their links to chronic disease risk.
Introduction
Recognition of the role of inflammation in the pathogenesis of chronic disease has led to inter-
est in biomarkers of inflammation. Elevated white blood cell count (WBC) is a classic bio-
marker of inflammation. It is associated with increased risk of death from all causes,
cardiovascular disease (CVD), and cancer, even after adjustment for confounders such as
smoking [1–3]. In a cohort of elderly women, elevated WBC and neutrophils and lower lym-
phocytes at baseline were associated with an increased risk of death over the next 5 years [4].
This suggests the neutrophil-to-lymphocyte ratio (NLR) may also be a good biomarker of
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inflammation; and, indeed, an elevated NLR correlates with severity and prognosis for CVD,
cancer, and other diseases [5, 6]. There has also been interest in the lymphocyte-to-monocyte
ratio (LMR) and the platelet-to-lymphocyte ratio (PLR) as inflammatory biomarkers [7, 8].
Besides predicting disease risk or severity, differential counts and ratios derived from them
also correlate with demographic and lifestyle factors such as age, sex, race, body mass index
(BMI), smoking, and diet [9–11], suggesting inflammatory biomarkers do not simply signal
end-stage illness but may also be involved in disease pathogenesis.
Reproductive events, including ages at menarche and menopause and number and timing
of births also affect chronic disease risk. It is widely assumed that estrogen excess or deficiency
explains this, especially for diseases where occurrence changes after menopause or risk in
women predominates, such as CVD or autoimmune disorders. However, at least for the vari-
ous autoimmune disorders, occurrence by age does not consistently track with menarche and
menopause and responses to pregnancy and exogenous estrogen also vary [12]. This suggests
that inflammatory/immune pathways may also be involved in associations between reproduc-
tive events and chronic disease. Surprisingly, the effects of past reproductive events on blood
counts and inflammatory markers have been an infrequent topic of research.
The National Health and Nutrition Examination Survey (NHANES) is an important source
of information on blood counts, inflammatory biomarkers derived from blood counts, and
reproductive events. In subsets of NHANES participants, data on the serum inflammatory bio-
markers, C-reactive protein (CRP), and total homocysteine (tHCY) are also available. Papers
from NHANES indicate total WBC, neutrophils, and lymphocytes decrease with age while
NLR, CRP, and tHCY increase [10, 13–15]. Compared to non-Hispanic whites and Hispanics,
non-Hispanic blacks have lower total WBCs and neutrophils [13]. Greater BMI and current
smoking lead to higher counts and inflammatory biomarkers [13]. In this study, we focus on
how reproductive events affect blood counts and inflammatory biomarkers derived from
blood counts using data from women who participated in NHANES. Serum CRP and tHCY
are included to determine how they are affected by reproductive events and their correlation
with blood counts.
Methods
The NHANES Division, within the U.S. Centers for Disease Control and Prevention, began in
1999 with 2-year data collection cycles. In each cycle, about 5,000 people are selected and
enrolled using a complex, multistage probability sampling design to create a representative
sample of the civilian, non-institutionalized US population. Participants provide health-related
data via questionnaires, physical exams, and laboratory assessments. People age 60 years and
older, African Americans, and Hispanics are over-sampled. Health interviews are conducted
in participants’ homes and exams in mobile examination centers where biologic samples are
also collected. In all cycles, an automated determination of complete blood count (CBC) was
performed using the Coulter method with different-generation Coulter Counters; and C-reac-
tive protein (CRP) was measured in six cycles using Latex enhanced nephelometry on the Beh-
ring Nephelometer II Analyzer [16]. Total plasma homocysteine (tHCY) was measured in four
survey cycles using high-performance liquid chromatography or commercial fluorescence
polarization immunoassay on different-generation Abbott systems [17].
Use of de-identified data, available to the public, was deemed Not Human Research by Part-
ners Human Research Committee, IRB Human Subjects Board; 2015P000935. We accessed
publically available data from 1999 through the 2011 cycles on women 20 years of age or older.
We excluded women who had incomplete CBC data (n = 2239) and those who did not com-
plete the reproductive-health questionnaire or had unknown menopausal status (n = 1533),
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for a final sample of 15,986 women. From the CBC data, we accessed total WBC, lymphocytes,
neutrophils, monocytes, hemoglobin, and platelets. Basophils and eosinophils were not
included because of insufficient variability in the distributions. Women were classified as pre-
menopausal if they reported regular periods in the past year or normally irregular cycles.
Women were classified as postmenopausal if they reported no periods in the past year due to
menopause or had a bilateral salpingo-oophorectomy (BSO) alone or at the time of hysterec-
tomy. Women who reported no periods in the past year because of a hysterectomy (without a
BSO) or because of a medical condition or treatment were classified as premenopausal if, at
survey, they were age<50 and postmenopausal if age50. Age at natural menopause was
assigned as the age at last period for those who either never had a BSO or had a BSO after their
periods stopped.
Statistical analysis
We calculated the following ratios: platelets-neutrophils (PNR), platelets-lymphocytes (PLR),
platelets-monocytes (PMR), neutrophils-lymphocytes (NLR), neutrophils-monocytes (NMR),
and lymphocytes-monocytes (LMR). These ratios, the blood count data, CRP, and tHCY were
log transformed (when appropriate) to normalize distributions. Outliers were identified and
excluded using the extreme studentized deviate many-outlier procedure [18]. To account for
differential weighting and the correlations within clustered data, we used SAS survey proce-
dures (SURVEYMEANS, SURVEYFREQ, and SURVEYREG) with the DOMAIN option for
analyzing subpopulations and used sampling weights according to NHANES guidelines [19].
We used linear regression models with counts and biomarkers as the dependent variables and
reproductive events as the independent variables. We tabulated adjusted arithmetic or geomet-
ric count and biomarker means by reproductive events. Based on previously published data
from NHANES [13–15], the following were considered potential confounders and adjusted
for in the linear models: age (continuous), race (Mexican American, other Hispanic, non-His-
panic white, non-Hispanic black, other races), BMI (<18.5, 18.5–24.9, 25–29.9, 30–34.9, 35–
39.9,40), and current smoking (no, yes). Since laboratory methods varied over time, survey
cycle (1999–2000, 2001–2, 2003–4, 2005–6, 2007–8, 2009–10, 2011–12) was also included.
Because counts and biomarkers differed by menopausal status, the effects of reproductive
events were examined separately for pre- and post menopausal women. Tests for trends for
exposures in ordinal categories were calculated by creating an ordinal variable in which the
median value or midpoint of each category was assigned to all participants in that group. For
example, for the trend test for age at first live birth, the values 18, 22, 26, 31 and 37 were used
to represent the categories <20, 20–24, 25–29, 30–34, and35, respectively. These were the
median ages within each category. This was done to minimize the effect of extreme values in
the tails of the exposure distributions on the associations between continuous reproductive
variables and biomarkers. P-values for categorical and trend variables were calculated with
partial sum of squares F-tests.
Results
Characteristics of the NHANES sample and their reproductive events are shown in Table 1.
Women in the 2011–2012 cycle had lower average parity. Predictably, younger women were
more likely to be nulliparous and have lower average parity, while older women were more
likely to report later menarche, more children, have had a hysterectomy, or be menopausal.
Non-Hispanic Blacks, Mexican-Americans and other Hispanics had: earlier menarche, earlier
age at first birth, and more children. Accordingly, potential confounding by survey cycle, age,
and race was considered when examining effects of reproductive events on the remaining
Reproductive events, blood counts, and biomarkers of inflammation
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variables in Table 1. Taller women reported later menarche and age at first birth. Heavier
women had earlier menarche, more children, earlier age at first birth, and greater likelihood of
having had a hysterectomy. Women who never smoked were more likely to be nulliparous.
Current smokers reported more children and earlier ages at first and last birth. Former smok-
ers were more likely to be menopausal and to have had a hysterectomy.
Effects of reproductive evens on counts and biomarkers are shown in Tables 2 and 3. Age at
menarche had no effects on counts among either pre- or postmenopausal women (Table 2).
Compared to nulliparous premenopausal women, those who had given birth had lower mono-
cytes, hemoglobin, and platelets; and, with increasing parity total WBC, neutrophils, and hemo-
globin declined. Parous postmenopausal women had more lymphocytes, without any changes
with increasing parity. An earlier age at first birth was associated with more platelets among
premenopausal women and higher lymphocytes and monocytes among postmenopausal
women. A later age at last livebirth was associated with lower WBC, neutrophils, monocytes,
and platelets among premenopausal women but no changes in postmenopausal women. A lon-
ger interval since last birth was associated with more monocyte and platelets among preemno-
pausal women and lower hemoglobin among postmenopausal women. Premenopausal women
who were currently using oral contraceptives (OCs) had higher lymphocytes, platelets, and
hemoglobin and fewer monocytes. All counts were altered in women who were currently preg-
nant and reversed in women who were currently nursing. Hysterectomy was associated with
higher hemoglobin and lower platelets among premenopausal women and more WBCs, lym-
phocytes, neutrophils, and platelets and lower hemoglobin among postmenopausal women.
Postmenopausal women with longer term OC use had higher lymphocytes and those who were
currently using estrogen-only HRT had more platelets. An early age at natural menopause was
associated with more WBCs and neutrophils, lower lymphocytes, hemoglobin, and platelets.
Premenopausal women with an earlier age at menarche had higher PMR and LMR
(Table 3). Compared to nulliparous premenopausal women, those who had given birth had
lower PNR, PLR, and tHCY and higher NMR, and LMR; and, with increasing parity, CRP
decreased. Parous postmenopasual women had lower PLR and NLR and greater LMR; and,
with increasing parity, CRP increased. An earlier age at first birth was associated with higher
tHCY among premenopausal women and lower PMR and higher CRP among postmenopausal
women. Among premenopausal women, a later age at last livebirth was associated with higher
LMR and lower CRP and tHCY; and PLR and tHCY increased and LMR decreased with more
years since last birth. Among postmenopausal women no changes in biomarker were seen
with either of these events. Premenopausal women who were currently using OCs had higher
PMR, NMR, LMR, and CRP. Similar to the story for counts, virtually all biomarkers were
altered in women who were currently pregnant and reversed in women who were currently
nursing. Hysterectomy was associated with lower PNR and PLR among premenopausal
women and with higher CRP among postmenopausal women. Longer term past use of OCs
was associated with lower NLR among postmenopausal women while current use of estrogen
only HRT was associated with higher CRP and lower tHCY. Early age at natural menopause
was associated with lower PNR and PMR and higher NLR and tHCY.
The results presented in Tables 2 and 3 are summarized in Table 4. In this table, the repro-
ductive events are shown in the second column for pre- and postmenopausal women sepa-
rately. An upward arrow indicates the event raised the count or biomarker and a downward
arrow indicates the event lowered the count or biomarker. Events which significantly affected
the counts or biomarkers are indicated by a bold arrow for an association with p value
<0.0003 and a non-bold arrow for p values0.0003 and0.05. A p-value of 0.0003, repre-
sents a Bonferroni-corrected p based on 12 inflammatory biomarkers from the blood count
data and the 12 reproductive variables.
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Table 2. Adjusted WBC, differential and platelet count means for reproductive characteristics by menopausal status.
N (%)1 WBC
Mean2
Lymphocytes
Mean2
Neutrophils
Mean2
Monocytes
Mean2
Hemoglobin
Mean2
Platelets
Mean2
Menopausal status
Premenopausal 8401 (57%) 7.71 2.15 4.63 0.57 13.29 286.5
Postmenopausal 7585 (43%) 7.27 2.27 4.08 0.54 13.66 275.6
p-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Among premenopausal women
Age at menarche
<11 788 (9%) 7.62 2.25 4.47 0.55 13.40 293.8
11 1092 (13%) 7.67 2.26 4.49 0.55 13.29 291.4
12–13 4207 (53%) 7.69 2.24 4.52 0.55 13.31 291.6
14–15 1673 (20%) 7.71 2.24 4.55 0.56 13.30 288.2
>15 456 (6%) 7.55 2.17 4.47 0.56 13.24 291.3
p-trend 0.86 0.08 0.64 0.11 0.11 0.25
Parity
Nulliparous 1809 (28%) 7.64 2.25 4.47 0.57 13.48 298.9
Parous 6047 (72%) 7.64 2.24 4.49 0.55 13.29 289.1
p-value 0.93 0.55 0.76 0.0002 <0.0001 0.0003
Parity
1 1662 (27%) 7.79 2.25 4.61 0.55 13.35 294.4
2 2119 (39%) 7.66 2.22 4.53 0.55 13.31 286.1
3 1413 (23%) 7.65 2.24 4.51 0.54 13.19 292.0
>3 853 (11%) 7.52 2.23 4.38 0.54 13.11 291.6
p-trend 0.02 0.80 0.02 0.18 <0.0001 0.67
Age at first live birth
<20 1192 (29%) 7.74 2.27 4.54 0.56 13.33 306.1
20–24 1234 (36%) 7.85 2.30 4.63 0.56 13.36 301.6
25–29 628 (22%) 7.63 2.25 4.48 0.55 13.35 296.1
30–34 280 (10%) 7.70 2.27 4.52 0.55 13.45 292.2
35 65 (3%) 7.78 2.26 4.67 0.54 13.44 295.9
p-trend 0.63 0.74 0.82 0.22 0.28 0.02
Age at last live birth
<25 1250 (32%) 7.91 2.28 4.68 0.57 13.41 304.3
25–29 973 (30%) 7.68 2.26 4.51 0.56 13.27 304.3
30–34 804 (26%) 7.69 2.30 4.49 0.55 13.33 301.3
35 371 (12%) 7.55 2.25 4.44 0.52 13.38 286.7
p-trend 0.03 0.94 0.04 <0.0001 0.68 0.02
Years since last live birth
0–4 1411 (32%) 7.71 2.30 4.50 0.54 13.37 292.7
5–9 698 (21%) 7.77 2.27 4.58 0.56 13.37 296.8
10–15 645 (236%) 7.76 2.26 4.60 0.56 13.30 311.7
16+ 644 (24%) 7.91 2.28 4.67 0.59 13.39 314.5
p-trend 0.31 0.73 0.27 0.002 0.99 0.0002
Oral contraceptive use
Never 2607 (26%) 7.67 2.22 4.53 0.56 13.28 291.5
Former 4778 (60%) 7.68 2.25 4.51 0.55 13.35 290.8
Current 926 (14%) 7.73 2.32 4.54 0.53 13.43 300.0
p-value3 0.43 0.006 0.7 <0.0001 0.008 0.005
(Continued )
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Table 2. (Continued)
N (%)1 WBC
Mean2
Lymphocytes
Mean2
Neutrophils
Mean2
Monocytes
Mean2
Hemoglobin
Mean2
Platelets
Mean2
Pregnant at time of blood collection
No 7256 (94%) 7.56 2.26 4.41 0.55 13.39 293.4
Yes 1145 (6%) 9.65 1.95 6.72 0.64 12.42 258.4
p-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Nursing at time of blood collection
No 8172 (98%) 7.70 2.23 4.55 0.55 13.32 290.8
Yes 229 (2%) 7.32 2.28 4.11 0.52 13.50 289.1
p-value 0.02 0.37 0.003 0.01 0.04 0.75
Hysterectomy
No 7669 (95%) 7.67 2.24 4.52 0.55 13.29 292.2
Yes 384 (5%) 7.84 2.31 4.59 0.55 13.69 283.2
p-value 0.24 0.17 0.49 0.93 <0.0001 0.05
Among postmenopausal women
Age at menarche
<11 488 (7%) 7.21 2.15 4.08 0.56 13.46 267.0
11 894 (12%) 7.09 2.12 4.04 0.55 13.49 264.5
12–13 3631 (52%) 7.14 2.15 4.03 0.56 13.52 270.5
14–15 1745 (21%) 7.11 2.12 4.04 0.56 13.47 266.5
>15 611 (8%) 7.33 2.19 4.16 0.56 13.47 270.0
p-trend 0.35 0.71 0.37 0.95 0.63 0.89
Parity
Nulliparous 727 (11%) 6.99 2.01 4.04 0.55 13.47 270.2
Parous 6721 (89%) 7.16 2.15 4.06 0.56 13.50 266.6
p-value 0.08 <0.0001 0.80 0.19 0.53 0.35
Parity
1 891 (15%) 7.09 2.15 3.99 0.55 13.54 266.7
2 1836 (33%) 7.19 2.15 4.08 0.56 13.55 266.2
3 1563 (26%) 7.19 2.17 4.06 0.56 13.49 268.1
4 951 (12%) 7.07 2.09 4.01 0.56 13.50 266.8
>4 1480 (15%) 7.19 2.18 4.06 0.56 13.47 264.9
p-trend 0.86 0.98 0.83 0.26 0.10 0.78
Age at first live birth
<20 1169 (31%) 7.27 2.24 4.07 0.58 13.62 275.3
20–24 1424 (42%) 7.05 2.16 3.95 0.57 13.70 272.8
25–29 625 (19%) 7.01 2.16 3.94 0.55 13.69 270.2
30–34 208 (6%) 7.10 2.13 4.02 0.57 13.71 273.4
35 83 (2%) 7.06 2.13 4.03 0.55 13.71 276.8
p-trend 0.10 0.02 0.45 0.003 0.23 0.60
Age at last live birth
<25 672 (22%) 7.15 2.20 3.97 0.58 13.63 274.6
25–29 932 (30%) 7.08 2.20 3.96 0.57 13.63 271.0
30–34 932 (26%) 7.16 2.21 4.02 0.57 13.76 274.6
35–39 646 (16%) 7.17 2.17 4.06 0.57 13.64 271.1
40 309 (6%) 7.19 2.16 4.07 0.58 13.69 274.5
p-trend 0.57 0.38 0.20 0.76 0.28 0.89
Years since last live birth
<28 870 (30%) 7.18 2.17 4.08 0.56 13.77 274.1
(Continued )
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Finally, Table 5 shows correlations of counts and ratios with CRP and tHCY. For counts,
the strongest positive correlations with CRP were with neutrophils and platelets. Surpris-
ingly, CRP was inversely correlated with PNR suggesting that more platelets relative to neu-
trophils signals lower inflammation. Positive correlations were also seen between CRP and
NLR, and NMR. For both counts and biomarkers derived from counts, correlations with
CRP were present and in the same direction in both pre- and postmenopausal women. In all
women, the strongest positive correlations with tHCY were inverse correlations with neu-
trophils, NMR, and NLR and a positive correlation with PNR. In all of these instances, the
correlations were stronger in premenopausal women with opposite or null correlations in
postmenopausal women.
Table 2. (Continued)
N (%)1 WBC
Mean2
Lymphocytes
Mean2
Neutrophils
Mean2
Monocytes
Mean2
Hemoglobin
Mean2
Platelets
Mean2
28–35 849 (24%) 7.06 2.17 3.96 0.57 13.75 273.1
36–43 878 (24%) 7.04 2.20 3.91 0.57 13.65 273.4
44+ 894 (22%) 7.30 2.23 4.09 0.59 13.52 271.8
p-trend 0.72 0.39 0.85 0.13 0.004 0.76
Oral contraceptive use
Never 3971 (45%) 7.37 2.19 4.23 0.56 13.61 266.1
5 years 2120 (31%) 7.34 2.19 4.19 0.57 13.71 270.7
>5–10 years 817 (13%) 7.38 2.23 4.22 0.56 13.64 267.4
>10 years 572 (10%) 7.42 2.28 4.16 0.57 13.54 272.8
p-value 0.64 0.04 0.58 0.77 0.19 0.23
Hormone replacement therapy
Never used 4422 (54%) 7.39 2.19 4.24 0.56 13.64 266.8
Formerly used 1844 (29%) 7.39 2.23 4.20 0.57 13.67 272.0
Currently using estrogen only 705 (12%) 7.49 2.24 4.27 0.57 13.62 278.0
Currently using other hormones 251 (5%) 7.55 2.18 4.39 0.58 13.74 269.7
p-value, current estrogen only4 0.27 0.38 0.61 0.45 0.69 0.004
p-value, current other hormones4 0.29 0.68 0.16 0.19 0.18 0.86
Hysterectomy
No 4242 (55%) 7.07 2.11 4.01 0.56 13.53 266.1
Yes 3318 (45%) 7.25 2.16 4.12 0.56 13.44 269.9
p-value 0.001 0.01 0.02 0.26 0.02 0.05
Age at natural menopause
<46 1087 (23%) 7.47 2.14 4.34 0.56 13.42 262.8
46–49 918 (22%) 7.47 2.11 4.38 0.56 13.51 266.6
50–52 1330 (31%) 7.19 2.11 4.13 0.54 13.49 260.6
>52 1075 (25%) 7.14 2.10 4.08 0.55 13.53 266.0
p-trend 0.0004 0.30 0.0002 0.06 0.08 0.52
1 Unweighted N and weighted percent.
2 Adjusted for data year (1999–2000, 2001–2, 2003–4, 2005–6, 2007–8, 2009–10, 2011–12), age (continuous) and race (Mexican American, other
Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI (<18.5, 18.5–24.9, 25–29.9, 30–34.9, 35–39.9,40), and current smoking (no, yes).
Units are 1000 cells/uL for WBC, lymphocytes, neutrophils, monocytes, and platelets and g/dL for hemoglobin.
3 Current users compared to those who never or formerly used oral contraceptives.
4 Referent category is those who never or formerly used hormone replacement therapy.
doi:10.1371/journal.pone.0172530.t002
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Table 3. Adjusted inflammatory marker means for reproductive characteristics by menopausal status.
Data available from 1999–2011 Data available from
1999–2010
Data available from
1999–2006
>N (%)1 PNR
Mean2
PLR
Mean2
PMR
Mean2
NLR
Mean2
NMR
Mean2
LMR
Mean2
N (%)1 CRP
Mean2
N (%)1 tHCY
Mean2
Menopausal status
Premenopausal 8401 (57%) 62.2 131.0 539.3 2.11 8.67 4.12 7222 (58%) 0.26 4650 (58%) 7.61
Postmenopausal 7585 (43%) 66.6 119.6 546.2 1.80 8.20 4.57 6393 (42%) 0.30 3944 (42%) 8.02
p-value 0.002 <0.0001 0.50 <0.0001 0.003 <0.0001 0.01 0.001
Among premenopausal
women
Age at menarche
<11 788 (9%) 63.8 126.7 573.1 1.99 8.98 4.52 667 (9%) 0.28 428 (9%) 6.80
11 1092 (13%) 62.9 124.9 567.5 1.99 9.03 4.54 931 (13%) 0.25 602 (13%) 6.56
12–13 4207 (53%) 62.4 125.9 564.0 2.02 9.03 4.48 3616 (53%) 0.26 2340 (54%) 6.55
14–15 1673 (20%) 61.3 124.7 551.9 2.03 9.00 4.43 1449 (20%) 0.26 895 (19%) 6.58
>15 456 (6%) 63.0 130.1 549.8 2.06 8.73 4.23 390 (6%) 0.28 241 (6%) 6.58
p-trend 0.24 0.52 0.04 0.13 0.35 0.004 0.77 0.52
Parity
Nulliparous 1809 (28%) 65.0 129.2 565.1 1.99 8.69 4.37 1497 (27%) 0.25 973 (28%) 6.97
Parous 6047 (72%) 62.3 125.1 566.1 2.01 9.09 4.53 5272 (73%) 0.26 3382 (72%) 6.58
p-value 0.008 0.01 0.88 0.53 0.002 0.009 0.34 <0.0001
Parity
1 1662 (27%) 61.9 126.9 572.0 2.05 9.24 4.51 1448 (27%) 0.31 980 (27%) 6.54
2 2119 (39%) 61.0 124.8 555.1 2.04 9.09 4.45 1825 (39%) 0.26 1152 (39%) 6.71
3 1413 (23%) 62.6 126.0 577.4 2.01 9.22 4.58 1248 (23%) 0.25 769 (23%) 6.70
>3 853 (11%) 64.5 126.8 574.8 1.96 8.91 4.53 751 (11%) 0.24 481 (12%) 6.57
p-trend 0.06 0.95 0.33 0.08 0.23 0.32 0.0001 0.55
Age at first live birth
<20 1192 (29%) 65.4 131.0 583.2 2.00 8.91 4.45 1181 (29%) 0.27 1185 (29%) 6.83
20–24 1234 (36%) 63.2 127.2 573.4 2.01 9.07 4.51 1222 (36%) 0.27 1227 (36%) 6.53
25–29 628 (22%) 63.9 127.0 578.3 1.99 9.05 4.55 626 (23%) 0.26 626 (22%) 6.47
30–34 280 (10%) 62.3 124.0 562.5 1.99 9.03 4.54 279 (10%) 0.27 280 (10%) 6.43
35 65 (3%) 61.5 127.2 591.9 2.07 9.62 4.65 64 (3%) 0.23 64 (3%) 6.67
p-trend 0.18 0.12 0.60 0.98 0.25 0.30 0.50 0.05
Age at last live birth
<25 1250 (32%) 63.0 129.2 564.5 2.05 8.96 4.37 1239 (32%) 0.29 1244 (32%) 6.78
25–29 973 (30%) 65.6 130.7 582.2 1.99 8.88 4.46 967 (30%) 0.27 971 (30%) 6.69
30–34 804 (26%) 65.1 126.9 592.5 1.95 9.10 4.67 797 (26%) 0.26 797 (26%) 6.41
35 371 (12%) 62.5 123.2 588.4 1.97 9.42 4.77 368 (12%) 0.22 369 (12%) 6.40
p-trend 0.87 0.08 0.06 0.09 0.07 0.0009 0.03 0.0005
Years since last live birth
0–4 1411 (32%) 63.0 123.2 577.0 1.96 9.15 4.68 1401 (32%) 0.27 1408 (32%) 6.26
5–9 698 (21%) 62.8 126.7 569.0 2.02 9.06 4.49 692 (21%) 0.23 690 (21%) 6.64
10–15 645 (23%) 65.8 134.1 594.3 2.04 9.03 4.43 641 (23%) 0.27 644 (23%) 7.02
16+ 644 (24%) 65.5 134.1 568.0 2.05 8.67 4.24 637 (24%) 0.31 639 (24%) 6.93
p-trend 0.14 0.004 0.90 0.22 0.05 0.003 0.09 0.0002
Oral contraceptive use
Never 2607 (26%) 62.5 127.3 560.50 2.04 8.97 4.4 2203 (25%) 0.23 1393 (25%) 6.69
Former 4778 (60%) 62.3 125.1 561.60 2.01 9.01 4.49 4142 (60%) 0.25 2696 (60%) 6.61
(Continued )
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Table 3. (Continued)
Data available from 1999–2011 Data available from
1999–2010
Data available from
1999–2006
>N (%)1 PNR
Mean2
PLR
Mean2
PMR
Mean2
NLR
Mean2
NMR
Mean2
LMR
Mean2
N (%)1 CRP
Mean2
N (%)1 tHCY
Mean2
Current 926 (14%) 64.1 125.5 613.90 1.96 9.58 4.89 796 (15%) 0.68 493 (14%) 6.66
p-value3 0.07 0.89 <0.0001 0.08 <0.0001 <0.0001 <0.0001 0.78
Pregnant at time of blood
collection
No 7256 (94%) 64.5 125.9 574.2 1.95 8.90 4.56 6135 (94%) 0.24 3673 (93%) 6.82
Yes 1145 (6%) 37.1 127.5 420.7 3.44 11.34 3.30 1087 (6%) 0.55 977 (7%) 4.64
p-value <0.0001 0.38 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Nursing at time of blood
collection
No 8172 (98%) 61.9 126 560.9 2.04 9.07 4.45 7016 (98%) 0.26 4505 (98%) 6.6
Yes 229 (2%) 68.1 122.7 597.7 1.80 8.77 4.87 206 (2%) 0.26 145 (2%) 6.78
p-value 0.005 0.39 0.05 0.004 0.34 0.01 0.88 0.31
Hysterectomy
No 7669 (95%) 62.6 126.2 565.3 2.01 9.03 4.48 6559 (95%) 0.26 4137 (95%) 6.63
Yes 384 (5%) 59.6 118.6 546.2 1.99 9.17 4.61 326 (5%) 0.27 189 (5%) 6.82
p-value 0.04 0.01 0.21 0.69 0.54 0.27 0.57 0.28
Among postmenopausal
women
Age at menarche
<11 488 (7%) 62.7 119.0 502.7 1.90 8.02 4.22 405 (7%) 0.31 223 (6%) 9.69
11 894 (12%) 62.9 119.9 508.5 1.91 8.09 4.24 760 (13%) 0.31 462 (13%) 9.16
12–13 3631 (52%) 64.5 121.0 513.3 1.88 7.96 4.24 3086 (52%) 0.32 1935 (53%) 9.17
14–15 1745 (21%) 63.2 120.6 508.8 1.91 8.05 4.22 1476 (21%) 0.33 874 (20%) 9.40
>15 611 (8%) 62.5 119.1 512.9 1.90 8.20 4.31 479 (7%) 0.34 313 (8%) 9.51
p-trend 0.50 0.88 0.79 0.61 0.40 0.69 0.20 0.21
Parity
Nulliparous 727 (11%) 64.1 129.0 523.0 2.01 8.16 4.06 622 (11%) 0.31 434 (12%) 9.60
Parous 6721 (89%) 63.0 119.1 506.1 1.89 8.03 4.25 5678 (89%) 0.33 3500 (88%) 9.34
p-value 0.45 <0.0001 0.07 0.004 0.37 0.01 0.35 0.18
Parity
1 891 (15%) 64.2 119.0 516.5 1.85 8.05 4.34 720 (15%) 0.32 441 (14%) 9.56
2 1836 (33%) 62.5 118.7 504.7 1.90 8.07 4.25 1499 (32%) 0.31 870 (30%) 9.43
3 1563 (26%) 63.3 118.4 507.1 1.87 8.02 4.28 1331 (25%) 0.34 787 (25%) 9.28
4 951 (12%) 63.8 122.4 508.8 1.92 7.98 4.16 805 (13%) 0.33 495 (13%) 9.35
>4 1480 (15%) 62.6 116.7 500.8 1.87 8.00 4.29 1323 (16%) 0.35 907 (18%) 9.35
p-trend 0.68 0.85 0.26 0.85 0.62 0.35 0.03 0.38
Age at first live birth
<20 1169 (31%) 65.1 118.6 498.1 1.82 7.65 4.20 1143 (31%) 0.36 1156 (31%) 9.45
20–24 1424 (42%) 66.5 121.5 509.4 1.83 7.66 4.19 1396 (42%) 0.35 1411 (42%) 9.32
25–29 625 (19%) 66.0 120.4 520.4 1.82 7.89 4.32 619 (19%) 0.32 619 (19%) 9.18
30–34 208 (6%) 65.2 123.3 508.3 1.89 7.79 4.12 207 (6%) 0.29 207 (6%) 9.24
35 83 (2%) 65.9 124.9 538.6 1.90 8.17 4.31 79 (2%) 0.30 81 (2%) 9.28
p-trend 0.76 0.13 0.01 0.38 0.09 0.54 0.01 0.28
Age at last live birth
<25 672 (22%) 66.7 120.2 505.6 1.80 7.58 4.21 661 (22%) 0.37 666 (22%) 9.54
(Continued)
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Table 3. (Continued)
Data available from 1999–2011 Data available from
1999–2010
Data available from
1999–2006
>N (%)1 PNR
Mean2
PLR
Mean2
PMR
Mean2
NLR
Mean2
NMR
Mean2
LMR
Mean2
N (%)1 CRP
Mean2
N (%)1 tHCY
Mean2
25–29 932 (30%) 66.1 119.1 504.6 1.80 7.63 4.24 914 (30%) 0.34 918 (30%) 9.34
30–34 932 (26%) 65.6 119.3 511.2 1.82 7.79 4.28 916 (26%) 0.35 926 (26%) 9.16
35–39 646 (16%) 64.0 119.9 499.5 1.87 7.81 4.16 634 (16%) 0.34 641 (16%) 9.33
40 309 (6%) 64.9 122.1 504.7 1.88 7.77 4.13 301 (6%) 0.39 305 (6%) 9.63
p-trend 0.11 0.77 0.91 0.12 0.13 0.68 0.99 0.40
Years since last live birth
<28 870 (30%) 64.3 120.9 514.8 1.88 8.00 4.26 855 (31%) 0.34 862 (30%) 9.41
28–35 849 (24%) 66.4 121.4 508.3 1.83 7.65 4.19 833 (24%) 0.35 839 (24%) 9.36
36–43 878 (24%) 67.4 119.8 510.0 1.78 7.57 4.26 863 (24%) 0.37 873 (24%) 9.01
44+ 894 (22%) 64.1 117.6 488.7 1.83 7.62 4.16 875 (22%) 0.35 882 (22%) 9.63
p-trend 0.85 0.45 0.13 0.44 0.06 0.56 0.65 0.71
Oral contraceptive use
Never 3971 (45%) 60.4 116.7 500.3 1.93 8.29 4.29 3438 (47%) 0.30 2302 (51%) 9.73
5 years 2120 (31%) 62.2 118.8 504.5 1.91 8.12 4.25 1750 (31%) 0.32 969 (29%) 9.5
>5–10 years 817 (13%) 61.1 115.8 507.6 1.90 8.31 4.38 671 (13%) 0.31 379 (12%) 9.45
>10 years 572 (10%) 63.5 115.8 508.3 1.82 8.01 4.39 449 (9%) 0.32 244 (8%) 9.60
p-value 0.14 0.41 0.37 0.04 0.41 0.09 0.51 0.47
Hormone replacement
therapy
Never used 4422 (54%) 60.5 117.3 502.8 1.94 8.31 4.29 3605 (52%) 0.29 2113 (48%) 9.81
Formerly used 1844 (29%) 62.4 117.7 505.1 1.89 8.09 4.29 1583 (29%) 0.30 909 (28%) 9.25
Currently using estrogen
only
705 (12%) 62.6 119.4 513.9 1.91 8.21 4.31 653 (13%) 0.53 531 (17%) 8.68
Currently using other
hormones
251 (5%) 59.3 119.2 492.2 2.01 8.29 4.13 242 (6%) 0.40 208 (8%) 8.73
p-value, current estrogen
only4
0.20 0.31 0.21 0.77 0.90 0.83 <0.0001 <0.0001
p-value, current other
hormones4
0.33 0.54 0.35 0.12 0.75 0.12 0.0007 <0.0001
Hysterectomy
No 4242 (55%) 63.8 121.1 509.5 1.90 7.98 4.21 3544 (55%) 0.29 2143 (53%) 9.41
Yes 3318 (45%) 62.7 119.6 509.8 1.91 8.13 4.26 2829 (45%) 0.38 1791 (47%) 9.32
p-value 0.12 0.23 0.94 0.69 0.15 0.13 <0.0001 0.41
Age at natural menopause
<46 1087 (23%) 58.0 117.7 495.3 2.03 8.53 4.21 923 (23%) 0.36 532 (23%) 9.86
46–49 918 (22%) 58.4 121.3 501.6 2.08 8.59 4.13 771 (22%) 0.37 473 (24%) 9.78
50–52 1330 (31%) 60.6 118.4 510.4 1.95 8.42 4.31 1094 (30%) 0.30 678 (31%) 9.50
>52 1075 (25%) 62.8 121.9 516.2 1.94 8.22 4.23 910 (25%) 0.34 546 (23%) 9.13
p-trend <0.0001 0.13 0.01 0.04 0.06 0.49 0.26 0.0002
1 Unweighted N and weighted percent.
2 Adjusted for data year (1999–2000, 2001–2, 2003–4, 2005–6, 2007–8, 2009–10, 2011–12), age (continuous) and race (Mexican American, other
Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI (<18.5, 18.5–24.9, 25–29.9, 30–34.9, 35–39.9,40), and current smoking (no, yes).
Units are mg/dL for CRP and umol/L for tHCY.
3 Current users compared to those who never or formerly used oral contraceptives.
4 Referent category is those who never or formerly used hormone replacement therapy.
doi:10.1371/journal.pone.0172530.t003
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Discussion
This analysis of cross-sectional data from NHANES reveals that reproductive events have both
short and long-term effects on blood counts, ratios of those counts, and the serum biomarkers,
CRP and tHCY. This study was prompted by observations that reproductive events have
major effects on chronic disease risk that may not be entirely explained by traditional interpre-
tations involving estrogen levels. Our discussion is organized around the following topics:
effects of reproductive events on counts and biomarkers in “real time”; residual effects of
reproductive event on counts and biomarkers and possible relevance to chronic disease risk;
and potential limitations of the study. We will conclude with an overview and suggestions for
future studies.
Real time effects of reproductive events
NHANES participants included women who were currently pregnant, breastfeeding or using
hormones allowing the effects of these events on counts and biomarkers to be studied in real
time. Pregnancy affected virtually all counts and biomarker, confirming that pregnancy is an
intensely “pro-inflammatory” state [20]. Most of the changes observed during pregnancy were
reversed in mothers who were nursing. Premenopausal women who were using OCs had sev-
eral changes in counts and biomarkers including elevated CRP. The link with CRP has been
Table 4. Effect of specified reproductive event on counts and biomarkers in pre- and postmenopausal women.
Menopausal status Event WBC L N M HGB P PNR PLR PMR NLR NMR LMR CRP tHCY
Premenopausal Decreasing age at menarche ↑ ↑
Nulliparity ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↑
Increasing parity ↓ ↓ ↓ ↓
Early age at first live birth ↑ ↑
Late age at last live birth ↓ ↓ ↓ ↓ ↑ ↓ ↓
Shorter time since last pregnancy ↓ ↓ ↓ ↑ ↓
Current OC use ↑ ↓ ↑ ↑ ↑ ↑ ↑ ↑
Pregnant ↑ ↓ ↑ ↑ ↓ ↓ ↓ ↓ ↑ ↑ ↓ ↑ ↓
Nursing ↓ ↓ ↓ ↑ ↑ ↓ ↑
Hysterectomy ↑ ↓ ↓
Postmenopausal Decreasing age at menarche
Nulliparity ↓ ↑ ↑ ↓
Increasing parity ↑
Early age at first live birth ↑ ↑ ↓ ↑
Late age at last live birth
Shorter time since last pregnancy ↑
Longer duration of OC use ↑ ↓
Current estrogen only HRT use ↑ ↓
Hysterectomy ↑ ↑ ↑ ↓ ↑
Early age at natural menopause ↑ ↑ ↓ ↓ ↑ ↑
↑ and↓ indicate count or maker increased or decreased, respectively, with the event in column 1.
Abbreviations: WBC: white blood cell, L: lymphocytes, N: neutrophils, M: monocytes, HGB: hemoglobin, P: platelets, PNR: platelet:neutrophil ratio, PLR:
platelet:lymphocyte ratio, PMR: platelet:monocyte ratio, NLR: neutrophil:lymphocyte ratio, NMR: neutrophil:monocyte ratio, LMR: lymphocyte:monocyte
ratio, CRP: C-reactive protein, HCY: homocysteine, OC: oral contraceptive, HRT: hormone replacement therapy.
↑ or↓ p-values <0.0003
↑ or↓ p-values0.0003 and <0.05
doi:10.1371/journal.pone.0172530.t004
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previously reported and may explain greater risk of thromboembolism in OC users[21]. Post-
menopausal women using estrogen-only HRT also had elevated CRP which also has been
reported previously [22].
Residual effects
Reproductive events also left residual effects on counts and inflammatory markers which may
be relevant to how menarche, menopause, and childbearing affect chronic disease risk.
Menarche. Early menarche is associated with increased risk of mortality from all-causes
and CVD [23, 24], breast cancer [25], and type II diabetes [26]. Obesity is an important con-
founder for these associations since early menarche predicts obesity in later life [27]. Correc-
tion for BMI attenuates risk for diabetes associated with early menarche [28, 29] and may
partly explain associations with cardiovascular disease [30] and breast cancer [25]. Adjusting
for BMI and age, early menarche has not been associated with higher estrogen levels in later
life in most studies [31–34]. In this study, an earlier age at menarche was associated with
higher PMR and LMR, but only in premenopausal women.
Menopause. Occurrence of menopause affected nearly all counts and inflammatory bio-
markers. Except for lymphocytes and hemoglobin, counts were lower in postmenopausal
women and most markers were also lower, except PNR and LMR. Women with an earlier age
at natural menopause had higher WBC and neutrophil counts and tHCY. This profile is
known to increase the risk for CVD and mortality from all causes [1, 4, 35] and could help
explain their association with early menopause [36, 37], especially since there is little evidence
Table 5. Pearson correlations between differential and platelet counts and their ratios and CRP and
tHCY.
All women Premenopausal Postmenopausal
CRP tHCY CRP tHCY CRP tHCY
Lymphocytes r 0.10 -0.01 0.10 0.11 0.12 -0.09
p <.0001 0.29 <.0001 <.0001 <.0001 <.0001
Neutrophils r 0.29 -0.21 0.32 -0.29 0.29 0.09
p <.0001 <.0001 <.0001 <.0001 <.0001 <.0001
Monocytes r 0.14 -0.03 0.13 -0.14 0.15 0.10
p <.0001 0.01 <.0001 <.0001 <.0001 <.0001
Hemoglobin r -0.07 0.13 -0.11 0.21 -0.05 -0.17
p <.0001 <.0001 <.0001 <.0001 <.0001 <.0001
Platelets r 0.18 0.01 0.19 0.16 0.20 -0.04
p <.0001 0.43 <.0001 <.0001 <.0001 0.01
PNR r -0.17 0.19 -0.19 0.34 -0.15 -0.11
p <.0001 <.0001 <.0001 <.0001 <.0001 <.0001
PLR r 0.03 0.01 0.04 0.02 0.02 0.05
p 0.0004 0.20 0.0002 0.17 0.16 0.002
PMR r -0.002 0.03 0.01 0.22 0.00 -0.12
p 0.80 0.02 0.62 <.0001 0.91 <.0001
NLR r 0.18 -0.17 0.22 -0.32 0.14 0.14
p <.0001 <.0001 <.0001 <.0001 <.0001 <.0001
NMR r 0.18 -0.19 0.23 -0.19 0.15 0.01
p <.0001 <.0001 <.0001 <.0001 <.0001 0.76
LMR r -0.03 0.01 -0.03 0.21 -0.02 -0.16
p 0.0004 0.23 0.004 <.0001 0.21 <.0001
doi:10.1371/journal.pone.0172530.t005
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that age at or time since menopause have any effects on future estrogen levels[31, 32, 34, 38,
39]. As opposed to CVD risk, early menopause decreases the risk for breast and endometrial
cancer [40].
Childbearing. A review of studies worldwide [41] found no consistent agreement on how
childbearing affects CVD risk. However, a study of U.S. cohorts concluded that risk for CVD
and coronary artery disease increased after 5 pregnancies after adjusting for age, educational
level, and weight [42]. Another large cohort study suggested the association may be J-shaped
with higher risk for nulliparous women, a nadir in risk for women with 2 children and increas-
ing risk with more pregnancies, especially after 5 [43]. Potentially relevant to these observa-
tions are higher tHCY levels for nulliparous premenopausal women and higher NLR and PLR
for nulliparous postmenopausal women. In addition, with more children CRP levels increased
in postmenopausal women but decreased among premenopausal women. Epidemiologic data
are more consistent for parity and cancer occurrence or mortality. With notable exceptions for
liver, cervix, and myeloma, nulliparous women are at greater risk for death from most types of
cancers, especially breast, endometrium, and ovary; and risk further decreases with increasing
parity [44–46]. Clearly relevant is the observation that parous women have lower estradiol and
estrone levels than nulliparous women and, among postmenopausal women, the levels may
further decline with increasing number of children [33, 34, 47]. However, possibly relevant, we
found higher PLR and lower LMR in pre- and postmenopausal women who were nulliparous.
Higher PLR and lower LMR predict worse survival after breast cancer [8, 48, 49].
Early age at first birth is associated with decreased risk for breast cancer—consistent with
observations that early age at first birth is associated with lower estrone and bioavailable estra-
diol levels among postmenopausal women [34]. First birth delayed after age 35 is less protec-
tive (or may actually increase risk) [50–52]. Lambe et al. studied women with 2 or more
pregnancies and found that breast cancer risk increased with both advancing age at first birth
and advancing age at last birth[53]. Elevated risk for breast cancer was more apparent in
women with an older age at and shorter interval since last birth—compatible with the theory
there is a transient increase in risk after any pregnancy which decreases and then becomes pro-
tective with more time since pregnancy [54]. In our study, an earlier age at first birth was asso-
ciated with lower PMR and higher monocytes and CRP among postmenopausal women.
Among premenopausal women, later age at and shorter interval since last birth was most
clearly associated with lower monocytes and higher LMR. Turning to CVD risk, research from
the Nurses’ Health Study, mostly involving women less than 60, found no effect of an early age
at first livebirth [55]. However, in an international study, first birth during adolescence was
associated with greater risk for diabetes, lung disease, and hypertension [56]. In our study, an
early age at first birth was associated with higher tHCY in premenopausal women and with
more monocytes in postmenopausal women. Notably, a Framingham study found that, among
leukocyte subsets, elevated monocytes were the best predictor of future CVD risk [57].
Study limitations
Misclassification, confounding, and false discovery are issues that should be considered in
interpreting the findings of this study. Although any self-reported data are subject to misclassi-
fication, reproductive events are memorable landmarks for women. In surveys repeated over
time, 75 to 95% of women correctly recalled within a year their previously reported ages at
menarche and natural or surgical menopause [58]. Based on prior observations from
NHANES, important confounders in examining the effects of reproductive events on blood
counts or inflammatory biomarkers include age, race, BMI, and current smoking and were
adjusted for in our analyses. The large size and number of variables in the NHANES sample
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used here provides considerable power to detect even small effects of reproductive events on
counts and inflammatory biomarkers. However, this also increases the likelihood of false posi-
tives; hence we highlighted those associations with a Bonferroni-corrected p value of 0.0003 in
Table 4.
Summary and future research. Epidemiologic evidence reviewed here reveals that repro-
ductive events have substantial impact on risks for chronic diseases, especially cardiovascular
diseases and cancers of the reproductive organs. It is intriguing that reproductive events often
track differently in their impact on CVD and cancer risk. Our analysis of NHANES data
reveals that reproductive events affect blood counts and inflammatory biomarkers in real time
as well as leaving residual effects. The fact that these changes are seen with simple morphologic
descriptors of white blood cell types suggests that further characterization of WBCs (e.g. T
cells, B cells, NK cells, etc.) could be informative. Focusing on the effects of reproductive events
on specific white cell types and the ratios derived from them in Table 4, it can be seen that 16
of the 20 bold arrows involve either monocytes or platelets or ratios that include monocytes or
platelets highlighting the potential importance of these two compartments. Relevant to this are
studies of platelets as immune cells and platelet-monocyte aggregates in coronary artery dis-
ease and cancer[59–61]. Clarifying the role of oxidative stress and lipoprotein receptors on a
variety of cells may help further bridge the connections between inflammation, immunity,
atherogeneisis, and tumorigneisis[62]. Further characterization of WBC subclasses and studies
of the effects of oxidative stress on platelets, monocytes, and the tissues they interact with may
reveal exactly how reproductive events mediate risk for a variety of chronic diseases expanding
on traditional interpretations involving hormone levels.
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